China Economic Network, Beijing, September 9-Bo Tuo Biology (688767.SH) recently disclosed its semi-annual report for 2023. In the first half of the year, the company's operating income was 0.212 billion billion yuan, down 86.08 percent from the same period last year; net profit attributable to shareholders of listed companies was 61.6029 million billion yuan, down 91.73 percent from the same period last year; net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 282200 yuan, down 92.74 percent from the same period last year; net cash flow from operating activities was 19.018 million billion yuan, down 102.31 percent from the same period last year.

In 2022, the company's operating income was 1.901 billion billion yuan, a year-on-year increase of 4.57; the net profit attributable to shareholders of listed companies was 0.774 billion billion yuan, a year-on-year decrease of 7.19; the net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 0.756 billion billion yuan, A year-on-year decrease of 8.42; net cash flow from operating activities was 0.703 billion billion yuan, a year-on-year decrease of 22.56.

Botuo Bio was listed on the Shanghai Stock Exchange on September 8, 2021. The number of new shares to be publicly issued is 26.6667 million, the issue price is 34.55 yuan per share, the total amount of funds raised is 0.921 billion yuan, and the net amount of funds raised is 0.829 billion yuan, which is 62.0781 million yuan less than the original proposed fund-raising.

according to the prospectus previously disclosed by botuo biology, the company originally planned to raise 0.891 billion billion yuan, which was intended to be used for "the expansion and upgrading of medical devices (in vitro diagnosis) with an annual output of 0.4 billion people", "the construction project of in vitro diagnosis research and development center", "the intelligent transformation construction project of in vitro diagnosis product production line" and "the construction project of marketing operation center".

the total cost of the company's public offering of new shares is 91.9641 million yuan (excluding value-added tax), of which Guotai Junan Securities receives a sponsorship and underwriting fee of 65.1887 million yuan.